A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients with High-Risk Cutaneous Squamous Cell Carcinoma (cSCC). J of Skin [Internet]. 2022 Nov. 16 [cited 2025 Apr. 18];6(6):482-96. Available from: https://skin.dermsquared.com/skin/article/view/1788